PD-1 immunotherapy better than chemo alone as first line lung cancer treatment

Bookmark and Share
Published: 3 Jun 2018
Views: 2383
Dr Gilberto Lopes - Oncoclinicas do Brasil, São Paulo, Brazil

Dr Lopes presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting that show front line pembrolizumab surpassed chemotherapy for lung cancer patients whose tumours had PD-L1 expression and no EGFR/ALK rearrangements.

For more on these results, watch his interview with ecancer and read our news coverage here.

Slides from this presentation are available here.